Document Detail


Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression.
MedLine Citation:
PMID:  15596194     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To evaluate prospectively the effects of intermittent androgen suppression (AS) on bone mineral density (BMD) in patients with prostate cancer without bone metastases. METHODS: A total of 19 hormone-naive patients with Stage D0 disease were treated with a luteinizing hormone-releasing hormone analog and an antiandrogen for 9 months, after which AS was discontinued. When the prostate-specific antigen level reached a predetermined threshold, AS was restarted. BMD was measured at baseline, after 9 months of AS, and at the end of the first off-treatment period or at 1 year, whichever occurred first. RESULTS: Of the 19 patients, 17 had normal BMD at baseline; 2 patients with osteopenia at baseline were excluded from the analysis. All but 1 of the 17 patients with normal baseline BMD experienced a decline in BMD in the lumbar spine or hip, or both, during AS. After 9 months, the mean BMD in these patients had decreased by 4.5% at the lumbar spine (P = 0.0007) and by 2.5% at the hip (P = 0.00013). After a median off-treatment period of 7.9 months, the mean change in BMD of the lumbar spine and hip relative to the post-AS values was 1.5% (P = 0.06) and -0.01% (P = 0.09), respectively. CONCLUSIONS: The observed loss of BMD during 9 months of AS is significantly greater than the expected 0.5% to 1% annual loss. Interruption of AS attenuated the rate of bone loss, although full recovery to the baseline BMD was not achieved in all patients. These data suggest that men treated with AS should undergo baseline and periodic follow-up BMD assessments, because significant bone loss can occur during the first 9 months of AS.
Authors:
Celestia Higano; Andrew Shields; Nathanael Wood; Judy Brown; Cathy Tangen
Related Documents :
24499754 - Association of mode of delivery with urinary incontinence and changes in urinary incont...
23447914 - Comparison of the efficacy and safety of surgical procedures utilizing autologous fasci...
9951784 - Prevention of appendicular bone loss in paget's disease following treatment with intrav...
10912534 - Implications of intermittent calcitriol therapy on growth and secondary hyperparathyroi...
9209234 - Tylenol extended relief overdose.
24382874 - Rehabilitation following arthroscopic rotator cuff repair: a review of current literature.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Urology     Volume:  64     ISSN:  1527-9995     ISO Abbreviation:  Urology     Publication Date:  2004 Dec 
Date Detail:
Created Date:  2004-12-14     Completed Date:  2005-07-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0366151     Medline TA:  Urology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1182-6     Citation Subset:  IM    
Affiliation:
University of Washington, Seattle Cancer Care Alliance, Seattle, Washington 98109, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Androgen Antagonists / therapeutic use*
Antineoplastic Agents, Hormonal / therapeutic use*
Bone Density* / drug effects
Flutamide / therapeutic use
Humans
Leuprolide / therapeutic use
Male
Middle Aged
Prostatic Neoplasms / drug therapy*
Testosterone / blood
Chemical
Reg. No./Substance:
0/Androgen Antagonists; 0/Antineoplastic Agents, Hormonal; 13311-84-7/Flutamide; 53714-56-0/Leuprolide; 58-22-0/Testosterone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10...
Next Document:  Vardenafil provides reliable efficacy over time in men with erectile dysfunction.